Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the spine in young adults. It is associated with excess cardiovascular and cerebrovascular morbidity.
To determine whether patients with AS are at increased risk for cardiovascular and cerebrovascular mortality.
Population-based retrospective cohort study using administrative health data.
21 473 patients with AS aged 15 years or older and 86 606 comparators without AS, matched for age, sex, and location of residence.
The primary outcome was a composite of cardiovascular and cerebrovascular death. Hazard ratios (HRs) for vascular death were calculated; adjusted for history of cancer, diabetes, dementia, inflammatory bowel disease, hypertension, chronic kidney disease, and peripheral vascular disease; and, among those aged 66 years or older, relevant drug therapies. Independent risk factors for vascular mortality were identified in patients with AS.
The mean age of patients with AS was 46 years, and 53% were male. Patients and comparators were followed for 166 920 and 686 461 patient-years, respectively. Adjusted HRs for vascular death in AS were 1.36 (95% CI, 1.13 to 1.65) overall, 1.46 (CI, 1.13 to 1.87) in men, and 1.24 (CI, 0.92 to 1.67) in women. Significant risk factors for vascular death were age; male sex; lower income; dementia; chronic kidney disease; peripheral vascular disease; and, among patients aged 65 years or older, lack of exposure to nonsteroidal anti-inflammatory drugs and statins.
Diagnosis codes for AS were not validated in Ontario.
Ankylosing spondylitis is associated with increased risk for vascular mortality. A comprehensive strategy to screen and treat modifiable vascular risk factors in AS is needed.
Primary Funding Source:
The Arthritis Program, University Health Network, Toronto; and The Arthritis Society, Canada.
Azevedo VF, Pecoits-Filho R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int. 2010;30:1411-6. [PMID: 20349072] doi: 10.1007/s00296-010-1416-3CrossrefMedlineGoogle Scholar
Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 1997;349:1391-2. [PMID: 9149715] CrossrefMedlineGoogle Scholar
Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-7. [PMID: 9732872] CrossrefMedlineGoogle Scholar
Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275-81. [PMID: 9734366] CrossrefMedlineGoogle Scholar
Bodnár N, Kerekes G, Seres I, Paragh G, Kappelmayer J, Némethné ZG, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol. 2011;38:723-9. [PMID: 21239756] doi: 10.3899/jrheum.100668CrossrefMedlineGoogle Scholar
Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford). 2008;47:1203-7. [PMID: 18524805] doi: 10.1093/rheumatology/ken198CrossrefMedlineGoogle Scholar
Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol. 2013;31:612-20. [PMID: 23406817] MedlineGoogle Scholar
Peters MJ, vanEijk IC, Smulders YM, Serne E, Dijkmans BA, van der Horst-Bruinsma IE, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2010;37:161-6. [PMID: 19955053] doi: 10.3899/jrheum.090667CrossrefMedlineGoogle Scholar
Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006;45:283-6. [PMID: 16204374] CrossrefMedlineGoogle Scholar
van Eijk IC, Peters MJ, Serné EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68:362-6. [PMID: 18390569] doi: 10.1136/ard.2007.086777CrossrefMedlineGoogle Scholar
Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-304. [PMID: 21834064] doi: 10.1002/art.30581CrossrefMedlineGoogle Scholar
Vinsonneau U, Brondex A, Mansourati J, Saraux A, Cornily JC, Arlès F, et al. Cardiovascular disease in patients with spondyloarthropathies. Joint Bone Spine. 2008;75:18-21. [PMID: 17913549] CrossrefMedlineGoogle Scholar
Lautermann D, Braun J. Ankylosing spondylitis—cardiac manifestations. Clin Exp Rheumatol. 2002;20:S11-5. [PMID: 12463440] MedlineGoogle Scholar
Dik VK, Peters MJ, Dijkmans PA, Van der Weijden MA, DeVries MK, Dijkmans BA, et al. The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. Scand J Rheumatol. 2010;39:38-41. [PMID: 20132069] doi: 10.3109/03009740903096101CrossrefMedlineGoogle Scholar
Peters MJ, Visman I, Nielen MM, VanDillen N, Verheij RA, van der Horst-Bruinsma IE, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis. 2010;69:579-81. [PMID: 19403516] doi: 10.1136/ard.2009.110593CrossrefMedlineGoogle Scholar
Huang YP, Wang YH, Pan SL. Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis—a population-based longitudinal follow-up study. PLoS One. 2013;8:e64155. [PMID: 23691161] doi: 10.1371/journal.pone.0064155CrossrefMedlineGoogle Scholar
Hollan I, Saatvedt K, Almdahl SM, Mikkelsen K, Moer R, Halvorsen P, et al. Spondyloarthritis: a strong predictor of early coronary artery bypass grafting. Scand J Rheumatol. 2008;37:18-22. [PMID: 18189190] doi: 10.1080/03009740701716868CrossrefMedlineGoogle Scholar
Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, Macey S, et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data. Semin Arthritis Rheum. 2012;42:140-5. [PMID: 22494565] doi: 10.1016/j.semarthrit.2012.02.008CrossrefMedlineGoogle Scholar
Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52:174-6. [PMID: 8484668] CrossrefMedlineGoogle Scholar
Khan MA, Khan MK, Kushner I. Survival among patients with ankylosing spondylitis: a life-table analysis. J Rheumatol. 1981;8:86-90. [PMID: 7218263] MedlineGoogle Scholar
Zochling J, Braun J. Mortality in ankylosing spondylitis. Clin Exp Rheumatol. 2008;26:S80-4. [PMID: 19026148] MedlineGoogle Scholar
Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27:S127-30. [PMID: 19822059] MedlineGoogle Scholar
Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63:1182-9. [PMID: 21391198] doi: 10.1002/art.30277CrossrefMedlineGoogle Scholar
Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70:1921-5. [PMID: 21784726] doi: 10.1136/ard.2011.151191CrossrefMedlineGoogle Scholar
Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor a inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645-54. [PMID: 23818109] doi: 10.1002/art.38070CrossrefMedlineGoogle Scholar
Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73:710-5. [PMID: 23505240] doi: 10.1136/annrheumdis-2012-202698CrossrefMedlineGoogle Scholar
Williams JI, Young W. A summary of studies on the quality of health care administrative databases in Canada.. In: Goel V, Williams J, Anderson G, Blackstien-Hirsch P, Fooks C, Naylor D, eds. Patterns of Health Care in Ontario: The ICES Practice Atlas. 2d ed. Ottawa, ON, Canada: Canadian Med Assoc; 1996:339-45. Google Scholar
Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto, Ontario, Canada: Institute for Clinical Evaluative Sciences; 2006. Google Scholar
Balzi D, Barchielli A, Battistella G, Gnavi R, Inio A, Tessari R, et al. [Ischemic heart disease prevalence estimated using a standard algorithm based on electronic health data in various areas of Italy]. Epidemiol Prev. 2008;32:22-9. [PMID: 18928235] MedlineGoogle Scholar
Roger VL, Killian J, Henkel M, Weston SA, Goraya TY, Yawn BP, et al. Coronary disease surveillance in Olmsted County objectives and methodology. J Clin Epidemiol. 2002;55:593-601. [PMID: 12063101] CrossrefMedlineGoogle Scholar
Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90:1398-403. [PMID: 15547012] CrossrefMedlineGoogle Scholar
Stavem K, Rønning OM. Survival of unselected stroke patients in a stroke unit compared with conventional care. QJM. 2002;95:143-52. [PMID: 11865169] CrossrefMedlineGoogle Scholar
Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative databases in identifying patients with hypertension. Open Med. 2007;1:e18-26. [PMID: 20101286] MedlineGoogle Scholar
Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25:512-6. [PMID: 11874939] CrossrefMedlineGoogle Scholar
Benchimol EI, Guttmann A, Mack DR, Nguyen GC, Marshall JK, Gregor JC, et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. J Clin Epidemiol. 2014;67:887-96. [PMID: 24774473] doi: 10.1016/j.jclinepi.2014.02.019CrossrefMedlineGoogle Scholar
Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV. Surname lists to identify South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study. BMC Med Res Methodol. 2010;10:42. [PMID: 20470433] doi: 10.1186/1471-2288-10-42CrossrefMedlineGoogle Scholar
Elit L, Saskin R, Raut R, Elliott L, Murphy J, Marrett L. Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecol Oncol. 2013;128:95-100. [PMID: 23085459] doi: 10.1016/j.ygyno.2012.10.006CrossrefMedlineGoogle Scholar
Wilkins R. PCCF+ Version 3G User's Guide (Geocodes/PCCF). Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files, Including Postal Codes to June 2001. Ottawa, Ontario, Canada: Statistics Canada; 2001. Google Scholar
Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330:960-2. [PMID: 15845982] CrossrefMedlineGoogle Scholar
Thakkar B, Hur K, Henderson WG, Oprian C. A method to generate Kaplan-Meier and adjusted survival curves using SAS. In: Proceedings of the Twenty-Third Annual SAS Users Group International (SUGI) Conference; Nashville, Tennessee;. 22–25 March 1998:226-8. Google Scholar
Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013;31:3069-75. [PMID: 23918942] doi: 10.1200/JCO.2012.46.7043CrossrefMedlineGoogle Scholar
Levy AR, Szabo SM, Rao SR, Cifaldi M, Maksymowych WP. Estimating the occurrence of renal complications among persons with ankylosing spondylitis. Arthritis Care Res (Hoboken). 2014;66:440-5. [PMID: 24106183] doi: 10.1002/acr.22176CrossrefMedlineGoogle Scholar
Wallis D, Haroon N, Ayearst R, Carty A, Inman RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol. 2013;40:2038-41. [PMID: 24187102] doi: 10.3899/jrheum.130588CrossrefMedlineGoogle Scholar
Tournadre A, Pereira B, Lhoste A, Dubost JJ, Ristori JM, Claudepierre P, et al. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res (Hoboken). 2013;65:1482-9. [PMID: 23463610] doi: 10.1002/acr.22001CrossrefMedlineGoogle Scholar
Radford EP, Doll R, Smith PG. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med. 1977;297:572-6. [PMID: 887115] CrossrefMedlineGoogle Scholar
Kaprove RE, Little AH, Graham DC, Rosen PS. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum. 1980;23:57-61. [PMID: 7352944] CrossrefMedlineGoogle Scholar
Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488-95. [PMID: 19525685] doi: 10.1097/EDE.0b013e3181a819a1CrossrefMedlineGoogle Scholar
Hamdi W, ChelliBouaziz M, Zouch I, Ghannouchi MM, Haouel M, Ladeb MF, et al. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2012;39:322-6. [PMID: 22247364] doi: 10.3899/jrheum.110792CrossrefMedlineGoogle Scholar
Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK, Ganotakis ES, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFα treatment: correlation with disease activity. Clin Exp Rheumatol. 2009;27:292-8. [PMID: 19473571] MedlineGoogle Scholar
Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH. Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. Rheumatol Int. 2014;34:265-70. [PMID: 24362789] doi: 10.1007/s00296-013-2927-5CrossrefMedlineGoogle Scholar
Kanathur N, Lee-Chiong T. Pulmonary manifestations of ankylosing spondylitis. Clin Chest Med. 2010;31:547-54. [PMID: 20692546] doi: 10.1016/j.ccm.2010.05.002CrossrefMedlineGoogle Scholar
Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum. 2012;64:1407-11. [PMID: 22139851] doi: 10.1002/art.33503CrossrefMedlineGoogle Scholar
Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79. [PMID: 23726390] doi: 10.1016/S0140-6736(13)60900-9CrossrefMedlineGoogle Scholar
Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-10. [PMID: 12020179] CrossrefMedlineGoogle Scholar
Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AM, Madsen OR, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2013. [PMID: 23749610] CrossrefMedlineGoogle Scholar
Singh JA, Holmgren AR, Krug H, Noorbaloochi S. Accuracy of the diagnoses of spondylarthritides in veterans affairs medical center databases. Arthritis Rheum. 2007;57:648-55. [PMID: 17471541] CrossrefMedlineGoogle Scholar
Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388-98. [PMID: 22127957] doi: 10.1002/art.33465CrossrefMedlineGoogle Scholar
Author, Article, and Disclosure Information
From the University of Toronto; Institute for Clinical Evaluative Sciences; Institute of Health Policy, Management and Evaluation; University Health Network; and Toronto Western Research Institute, Toronto, and McMaster University, Hamilton, Ontario, Canada.
Disclaimer: The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI; however, the analyses, conclusions, opinions, and statements expressed herein are those of the authors and not necessarily those of CIHI.
Grant Support: By the Arthritis Center of Excellence; The Arthritis Society; and ICES, which is funded by a grant from the Ontario Ministry of Health and Long-Term Care.
Disclosures: Dr. N. Haroon reports grants from the Arthritis Society, nonfinancial support from the Institute of Clinical Evaluative Sciences, and grants from Toronto General and Western Hospital Foundation during the conduct of the study and personal fees from AbbVie, Amgen, Celgene, Janssen, UCB, and Hospira outside the submitted work. Authors not named here have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOf InterestForms.do?msNum=M14-2470.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer.
Reproducible Research Statement:Study protocol and statistical code: Available from Dr. Nigil Haroon (e-mail, Nigil.
Corresponding Author: Nigil Haroon, MD, PhD, DM, Toronto Western Hospital, 1E-425, 399 Bathurst Street, Toronto Western Hospital, Toronto, Ontario M5T 2S8, Canada; e-mail, Nigil.
Current Author Addresses: Dr. N.N. Haroon: Department of Medicine, University of Toronto, 200 Elizabeth Street, 7th Floor, OP Program, Toronto, Ontario M5G 2C4, Canada.
Mr. Paterson and Dr. Li: Institute for Clinical Evaluative Sciences, G106-2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Dr. Inman: Toronto Western Hospital, 1EW-423, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada.
Dr. N. Haroon: Toronto Western Hospital, 1EW-425, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada.
Author Contributions: Conception and design: N.N. Haroon, J.M. Paterson, P. Li, R.D. Inman, N. Haroon.
Analysis and interpretation of the data: N.N. Haroon, J.M. Paterson, P. Li, R.D. Inman, N. Haroon.
Drafting of the article: N.N. Haroon, R.D. Inman, N. Haroon.
Critical revision of the article for important intellectual content: N.N. Haroon, J.M. Paterson, P. Li, R.D. Inman, N. Haroon.
Final approval of the article: N.N. Haroon, J.M. Paterson, R.D. Inman, N. Haroon.
Statistical expertise: N.N. Haroon, P. Li, N. Haroon.
Obtaining of funding: R.D. Inman, N. Haroon.
Administrative, technical, or logistic support: J.M. Paterson, P. Li, R.D. Inman.
This article was published online first at www.annals.org on 11 August 2015.